View Future GrowthMaking Science Group 過去の業績過去 基準チェック /06Making Science Groupの収益は年間平均-31.8%の割合で減少していますが、 Media業界の収益は年間 増加しています。収益は年間8.1% 26.6%割合で 増加しています。主要情報-31.78%収益成長率-36.33%EPS成長率Media 業界の成長14.69%収益成長率26.61%株主資本利益率-17.07%ネット・マージン-2.23%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • May 23Full year 2024 earnings released: €0.20 loss per share (vs €0.46 loss in FY 2023)Full year 2024 results: €0.20 loss per share (improved from €0.46 loss in FY 2023). Revenue: €273.5m (up 16% from FY 2023). Net loss: €1.72m (loss narrowed 55% from FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 24Second quarter 2023 earnings releasedSecond quarter 2023 results: €0.12 loss per share. Revenue: €57.0m (up 15% from 2Q 2022). Net loss: €1.03m (loss widened 35% from 2Q 2022).Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €213.4m (up 89% from FY 2021). Net loss: €4.99m (loss widened 43% from FY 2021).Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.9m (up 130% from FY 2019). Net income: €1.54m (up 302% from FY 2019). Profit margin: 2.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue.すべての更新を表示Recent updatesお知らせ • May 11Making Science Group, S.A., Annual General Meeting, Jun 11, 2026Making Science Group, S.A., Annual General Meeting, Jun 11, 2026. Location: lopez de hoyos 135, 3, madrid., Spainお知らせ • Mar 25Making Science Group, S.A. announces Annual dividend, payable on April 30, 2026Making Science Group, S.A. announced Annual dividend of EUR 0.1799 per share payable on April 30, 2026, ex-date on April 28, 2026 and record date on April 29, 2026.お知らせ • Feb 17Making Science Group, S.A., Annual General Meeting, Mar 18, 2026Making Science Group, S.A., Annual General Meeting, Mar 18, 2026. Location: calle lopez de hoyos 135, 3., madrid SpainNew Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.3% average weekly change). Market cap is less than US$100m (€67.0m market cap, or US$78.0m).New Risk • Oct 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.2% average weekly change). Market cap is less than US$100m (€78.0m market cap, or US$91.3m).Reported Earnings • May 23Full year 2024 earnings released: €0.20 loss per share (vs €0.46 loss in FY 2023)Full year 2024 results: €0.20 loss per share (improved from €0.46 loss in FY 2023). Revenue: €273.5m (up 16% from FY 2023). Net loss: €1.72m (loss narrowed 55% from FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • May 12Making Science Group, S.A., Annual General Meeting, Jun 12, 2025Making Science Group, S.A., Annual General Meeting, Jun 12, 2025. Location: calle lopez de hoyos 135, 3., madrid SpainNew Risk • May 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€77.0m market cap, or US$86.6m).New Risk • Feb 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Market cap is less than US$100m (€81.4m market cap, or US$84.7m).お知らせ • Jan 09Making Science Launches RAISING, Its New AI Technology Division to Power Marketing StrategiesMaking Science has announced the launch of RAISING, its new technology division that combines the company's business expertise with data science to develop advanced solutions based on Artificial Intelligence. This new venture aims to transform brands' marketing strategies through predictive, generative, and automated AI technologies, optimizing results throughout the entire funnel. RAISING integrates cutting-edge tools that reinforce its technology proposition. These include ad-machina, Making Science's technology that uses generative AI to automate the creation and multi-platform activation of personalized ads in real-time. The tool has proven its effectiveness on platforms such as Performance Max and Meta, achieving up to 30% more conversions compared to traditional methods. Its advanced functionalalities allow the dynamic adaptation of text, image, or video ads to market and user needs, incorporating detailed data analysis, automatic translation, and large-scale optimization, ensuring more effective and profitable campaigns, which relevant companies such as Banco Santander or MediaMarkt have already integrated into their business plans. Another key product of this new division is Gauss AI, which is designed to predict user behavior and optimize distribution, measurement, and media planning strategies. This system helps companies to identify the most relevant and profitable interactions, increasing the effectiveness of their campaigns. Trust Generative AI is positioned as a versatile and secure tool for content generation at scale, automating internal and external processes in areas such as marketing, SEO, and human resources while ensuring regulatory compliance and ultimate human control. The launch of RAISING reinforces Making Science's position as a benchmark in technological innovation applied to marketing.New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (€68.6m market cap, or US$71.5m).New Risk • Nov 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.2% average weekly change). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (€73.9m market cap, or US$78.1m).お知らせ • Nov 19Making Science Announces Management ChangesMaking Science has announced the appointment of Nick Waters as CEO for the UK, Northern and Central Europe. Based in London, with extensive experience in business leadership and the technology market, Waters will be responsible for driving the company’s growth and expansion across Europe. Due to take up the role in February 2025, Waters brings over 20 years of experience in international media, digital, and advertising. He joins Making Science from Ebiquity Plc, where he was Group Chief Executive Officer. Before that, he spent 10 years at Dentsu Aegis Network – latterly as Executive Chairman UK & Ireland, and 12 years at Mindshare, rising to regional CEO of Europe, Middle East, and Africa. Waters’ appointment follows the announcement of Marcus Cooper as Business Director, UK, Brad Beiter as SVP of Customer Management, and José Luis Pulpón, (ex Google) as Managing Director for Making Science, Spain. These strategic hires play a vital role in Making Science’s global expansion to ensure the delivery of cutting-edge digital transformation solutions for its clients across industries.Reported Earnings • Oct 24Second quarter 2023 earnings releasedSecond quarter 2023 results: €0.12 loss per share. Revenue: €57.0m (up 15% from 2Q 2022). Net loss: €1.03m (loss widened 35% from 2Q 2022).New Risk • Aug 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (4.1% average weekly change). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (€71.4m market cap, or US$78.7m).New Risk • Jul 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (€69.6m market cap, or US$75.4m).お知らせ • May 21Making Science Group, S.A., Annual General Meeting, Jun 17, 2024Making Science Group, S.A., Annual General Meeting, Jun 17, 2024. Location: calle lopez de hoyos 135, 3., madrid SpainNew Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€74.2m market cap, or US$80.6m).New Risk • May 16New major risk - Revenue and earnings growthEarnings have declined by 65% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€74.4m market cap, or US$80.9m).New Risk • Apr 18New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Market cap is less than US$100m (€72.8m market cap, or US$77.7m).New Risk • Nov 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (5.3% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€79.0m market cap, or US$84.7m).New Risk • Oct 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€69.0m market cap, or US$73.0m).New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 3.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (3.8% average weekly change). Market cap is less than US$100m (€69.6m market cap, or US$73.0m).分析記事 • May 18Is Making Science Group (BME:MAKS) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €213.4m (up 89% from FY 2021). Net loss: €4.99m (loss widened 43% from FY 2021).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to €13.80, the stock trades at a trailing P/E ratio of 67x. Average trailing P/E is 7x in the Media industry in Spain. Total loss to shareholders of 45% over the past year.分析記事 • Jun 14Estimating The Fair Value Of Making Science Group, S.A. (BME:MAKS)Today we will run through one way of estimating the intrinsic value of Making Science Group, S.A. ( BME:MAKS ) by...Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.分析記事 • Feb 25Making Science Group (BME:MAKS) Could Become A Multi-BaggerTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...分析記事 • Jun 23If You Like EPS Growth Then Check Out Making Science Group (BME:MAKS) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...分析記事 • May 31Here's Why Making Science Group (BME:MAKS) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 19Shareholders Would Enjoy A Repeat Of Making Science Group's (BME:MAKS) Recent Growth In ReturnsFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.9m (up 130% from FY 2019). Net income: €1.54m (up 302% from FY 2019). Profit margin: 2.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Feb 28New 90-day high: €28.00The company is up 103% from its price of €13.80 on 30 November 2020. The Spanish market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 10.0% over the same period.Is New 90 Day High Low • Feb 06New 90-day high: €15.50The company is up 20% from its price of €12.90 on 06 November 2020. The Spanish market is up 16% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Media industry, which is also up 20% over the same period.Is New 90 Day High Low • Nov 04New 90-day high: €12.30The company is up 108% from its price of €5.90 on 05 August 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 5.0% over the same period.Is New 90 Day High Low • Oct 09New 90-day high: €7.05The company is up 19% from its price of €5.90 on 10 July 2020. The Spanish market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 13% over the same period.お知らせ • Jul 17Making Science Group, S.A. (BME:MAKS) signed a deal to acquire Salesforce associated assets of Cloudforms SL.Making Science Group, S.A. (BME:MAKS) signed a deal to acquire Salesforce associated assets of Cloudforms SL on July 14, 2020. After acquisition, Making Science expects a gross margin growth of €0.5 million and EBITDA growth of €0.1 million over the next 12 months.収支内訳Making Science Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BME:MAKS 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 25348-80030 Sep 25331-6-1030 Jun 25315-4-1031 Mar 25294-3-1031 Dec 24271-30030 Sep 24261-21030 Jun 24251-12031 Mar 24244-22031 Dec 23236-41030 Sep 23230-3-3030 Jun 23225-1-7031 Mar 23217-1-4031 Dec 22210-10030 Sep 22187-27030 Jun 22165-413031 Mar 22139-411031 Dec 21113-39030 Sep 2198-2-23030 Jun 21830-11031 Mar 21711-4031 Dec 205923031 Dec 1935128031 Dec 185020質の高い収益: MAKSは現在利益が出ていません。利益率の向上: MAKSは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MAKSは利益が出ておらず、過去 5 年間で損失は年間31.8%の割合で増加しています。成長の加速: MAKSの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: MAKSは利益が出ていないため、過去 1 年間の収益成長をMedia業界 ( -3% ) と比較することは困難です。株主資本利益率高いROE: MAKSは現在利益が出ていないため、自己資本利益率 ( -17.07% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMedia 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 00:30終値2026/06/18 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Making Science Group, S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 23Full year 2024 earnings released: €0.20 loss per share (vs €0.46 loss in FY 2023)Full year 2024 results: €0.20 loss per share (improved from €0.46 loss in FY 2023). Revenue: €273.5m (up 16% from FY 2023). Net loss: €1.72m (loss narrowed 55% from FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 24Second quarter 2023 earnings releasedSecond quarter 2023 results: €0.12 loss per share. Revenue: €57.0m (up 15% from 2Q 2022). Net loss: €1.03m (loss widened 35% from 2Q 2022).
Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €213.4m (up 89% from FY 2021). Net loss: €4.99m (loss widened 43% from FY 2021).
Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.9m (up 130% from FY 2019). Net income: €1.54m (up 302% from FY 2019). Profit margin: 2.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue.
お知らせ • May 11Making Science Group, S.A., Annual General Meeting, Jun 11, 2026Making Science Group, S.A., Annual General Meeting, Jun 11, 2026. Location: lopez de hoyos 135, 3, madrid., Spain
お知らせ • Mar 25Making Science Group, S.A. announces Annual dividend, payable on April 30, 2026Making Science Group, S.A. announced Annual dividend of EUR 0.1799 per share payable on April 30, 2026, ex-date on April 28, 2026 and record date on April 29, 2026.
お知らせ • Feb 17Making Science Group, S.A., Annual General Meeting, Mar 18, 2026Making Science Group, S.A., Annual General Meeting, Mar 18, 2026. Location: calle lopez de hoyos 135, 3., madrid Spain
New Risk • Dec 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.3% average weekly change). Market cap is less than US$100m (€67.0m market cap, or US$78.0m).
New Risk • Oct 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.2% average weekly change). Market cap is less than US$100m (€78.0m market cap, or US$91.3m).
Reported Earnings • May 23Full year 2024 earnings released: €0.20 loss per share (vs €0.46 loss in FY 2023)Full year 2024 results: €0.20 loss per share (improved from €0.46 loss in FY 2023). Revenue: €273.5m (up 16% from FY 2023). Net loss: €1.72m (loss narrowed 55% from FY 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • May 12Making Science Group, S.A., Annual General Meeting, Jun 12, 2025Making Science Group, S.A., Annual General Meeting, Jun 12, 2025. Location: calle lopez de hoyos 135, 3., madrid Spain
New Risk • May 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€77.0m market cap, or US$86.6m).
New Risk • Feb 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Market cap is less than US$100m (€81.4m market cap, or US$84.7m).
お知らせ • Jan 09Making Science Launches RAISING, Its New AI Technology Division to Power Marketing StrategiesMaking Science has announced the launch of RAISING, its new technology division that combines the company's business expertise with data science to develop advanced solutions based on Artificial Intelligence. This new venture aims to transform brands' marketing strategies through predictive, generative, and automated AI technologies, optimizing results throughout the entire funnel. RAISING integrates cutting-edge tools that reinforce its technology proposition. These include ad-machina, Making Science's technology that uses generative AI to automate the creation and multi-platform activation of personalized ads in real-time. The tool has proven its effectiveness on platforms such as Performance Max and Meta, achieving up to 30% more conversions compared to traditional methods. Its advanced functionalalities allow the dynamic adaptation of text, image, or video ads to market and user needs, incorporating detailed data analysis, automatic translation, and large-scale optimization, ensuring more effective and profitable campaigns, which relevant companies such as Banco Santander or MediaMarkt have already integrated into their business plans. Another key product of this new division is Gauss AI, which is designed to predict user behavior and optimize distribution, measurement, and media planning strategies. This system helps companies to identify the most relevant and profitable interactions, increasing the effectiveness of their campaigns. Trust Generative AI is positioned as a versatile and secure tool for content generation at scale, automating internal and external processes in areas such as marketing, SEO, and human resources while ensuring regulatory compliance and ultimate human control. The launch of RAISING reinforces Making Science's position as a benchmark in technological innovation applied to marketing.
New Risk • Dec 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (€68.6m market cap, or US$71.5m).
New Risk • Nov 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.2% average weekly change). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Market cap is less than US$100m (€73.9m market cap, or US$78.1m).
お知らせ • Nov 19Making Science Announces Management ChangesMaking Science has announced the appointment of Nick Waters as CEO for the UK, Northern and Central Europe. Based in London, with extensive experience in business leadership and the technology market, Waters will be responsible for driving the company’s growth and expansion across Europe. Due to take up the role in February 2025, Waters brings over 20 years of experience in international media, digital, and advertising. He joins Making Science from Ebiquity Plc, where he was Group Chief Executive Officer. Before that, he spent 10 years at Dentsu Aegis Network – latterly as Executive Chairman UK & Ireland, and 12 years at Mindshare, rising to regional CEO of Europe, Middle East, and Africa. Waters’ appointment follows the announcement of Marcus Cooper as Business Director, UK, Brad Beiter as SVP of Customer Management, and José Luis Pulpón, (ex Google) as Managing Director for Making Science, Spain. These strategic hires play a vital role in Making Science’s global expansion to ensure the delivery of cutting-edge digital transformation solutions for its clients across industries.
Reported Earnings • Oct 24Second quarter 2023 earnings releasedSecond quarter 2023 results: €0.12 loss per share. Revenue: €57.0m (up 15% from 2Q 2022). Net loss: €1.03m (loss widened 35% from 2Q 2022).
New Risk • Aug 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (4.1% average weekly change). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (€71.4m market cap, or US$78.7m).
New Risk • Jul 10New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (8.3% increase in shares outstanding). Market cap is less than US$100m (€69.6m market cap, or US$75.4m).
お知らせ • May 21Making Science Group, S.A., Annual General Meeting, Jun 17, 2024Making Science Group, S.A., Annual General Meeting, Jun 17, 2024. Location: calle lopez de hoyos 135, 3., madrid Spain
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€74.2m market cap, or US$80.6m).
New Risk • May 16New major risk - Revenue and earnings growthEarnings have declined by 65% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 65% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€74.4m market cap, or US$80.9m).
New Risk • Apr 18New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Market cap is less than US$100m (€72.8m market cap, or US$77.7m).
New Risk • Nov 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (5.3% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€79.0m market cap, or US$84.7m).
New Risk • Oct 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (€69.0m market cap, or US$73.0m).
New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 3.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 69% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (3.8% average weekly change). Market cap is less than US$100m (€69.6m market cap, or US$73.0m).
分析記事 • May 18Is Making Science Group (BME:MAKS) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Apr 20Full year 2022 earnings releasedFull year 2022 results: Revenue: €213.4m (up 89% from FY 2021). Net loss: €4.99m (loss widened 43% from FY 2021).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to €13.80, the stock trades at a trailing P/E ratio of 67x. Average trailing P/E is 7x in the Media industry in Spain. Total loss to shareholders of 45% over the past year.
分析記事 • Jun 14Estimating The Fair Value Of Making Science Group, S.A. (BME:MAKS)Today we will run through one way of estimating the intrinsic value of Making Science Group, S.A. ( BME:MAKS ) by...
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
分析記事 • Feb 25Making Science Group (BME:MAKS) Could Become A Multi-BaggerTo find a multi-bagger stock, what are the underlying trends we should look for in a business? Amongst other things...
分析記事 • Jun 23If You Like EPS Growth Then Check Out Making Science Group (BME:MAKS) Before It's Too LateIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
分析記事 • May 31Here's Why Making Science Group (BME:MAKS) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Apr 19Shareholders Would Enjoy A Repeat Of Making Science Group's (BME:MAKS) Recent Growth In ReturnsFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €58.9m (up 130% from FY 2019). Net income: €1.54m (up 302% from FY 2019). Profit margin: 2.6% (up from 1.5% in FY 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Feb 28New 90-day high: €28.00The company is up 103% from its price of €13.80 on 30 November 2020. The Spanish market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Feb 06New 90-day high: €15.50The company is up 20% from its price of €12.90 on 06 November 2020. The Spanish market is up 16% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Media industry, which is also up 20% over the same period.
Is New 90 Day High Low • Nov 04New 90-day high: €12.30The company is up 108% from its price of €5.90 on 05 August 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 5.0% over the same period.
Is New 90 Day High Low • Oct 09New 90-day high: €7.05The company is up 19% from its price of €5.90 on 10 July 2020. The Spanish market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Media industry, which is up 13% over the same period.
お知らせ • Jul 17Making Science Group, S.A. (BME:MAKS) signed a deal to acquire Salesforce associated assets of Cloudforms SL.Making Science Group, S.A. (BME:MAKS) signed a deal to acquire Salesforce associated assets of Cloudforms SL on July 14, 2020. After acquisition, Making Science expects a gross margin growth of €0.5 million and EBITDA growth of €0.1 million over the next 12 months.